Nature Cancer January issue cover.

Lipids as mediators of cancer progression and metastasis

  • Felix C. E. Vogel
  • Adriano B. Chaves-Filho
  • Almut Schulze
Review Article

Announcements

  • Microscopy image of colorized immune cells.

    Join us for a Nature Conference on cancer immunotherapy, co-organized by Dana Farber Cancer Institute, Nature Cancer, Nature Immunology, Nature Medicine and Nature Immunology on June 10-12 2024 in Boston. Submit your abstract by April 12, 2024.

  • Nature Cancer December issue cover

    We bid farewell to 2023 with a Focus issue comprising news and comment articles on the biggest advances and challenges of the year and highlights from the published literature.

  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

  • Image displaying the registration page for the conference

    Join us for a virtual meeting bringing together experts across disciplines to discuss developments in antigen discovery, preclinical vaccine development and clinical advances in cancer vaccine therapy, and reflect on the ongoing challenges and necessities in the field.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

  • Gold-standard cancer data management is pivotal to enable precision medicine for European citizens. Achieving this goal relies on key elements: adopting standardized data formats, ensuring robust data privacy, educating professionals about the infrastructure’s benefits and leveraging cutting-edge technologies to transform cancer care.

    • Macha Nikolski
    • Eivind Hovig
    • Gary Saunders
    Comment
  • Drug regulatory agencies in the USA and Europe have mechanisms to provide patients faster access to novel treatments, expecting that follow-up trials will confirm clinically meaningful results. However, some early approvals are subsequently withdrawn. Here we discuss the insights gained from withdrawn accelerated approvals for oncologic agents in the past decade.

    • George S. Mellgard
    • Tito Fojo
    • Susan E. Bates
    Comment
  • Anirban Maitra obtained his medical degree from the All India Institute of Medical Sciences, New Delhi, in 1996; this was followed by residency and fellowships in pathology at the University of Texas Southwestern Medical Center, Dallas, and Johns Hopkins University School of Medicine, Baltimore. From 2002 to 2013, he served as faculty in the departments of pathology and oncology at Johns Hopkins, before being recruited to the MD Anderson Cancer Center as Professor of Pathology and Translational Molecular Pathology and Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research.

    • Anirban Maitra
    Turning Points
  • Rebecca Fitzgerald completed her medical degree at the University of Cambridge, followed by doctoral research at Stanford University, and then postdoctoral research alongside specialist training in gastroenterology at Barts and the London Hospitals. She started her own independent group the MRC Cancer Unit in 2001 with an honorary gastroenterology consultant position at Addenbrooke’s Hospital. In 2014, she was elected to chair in cancer prevention, and in 2022 inaugural director of the department of oncology at the Early Cancer Institute, University of Cambridge.

    • Rebecca Fitzgerald
    Turning Points

Nature Careers

Science jobs

Advertisement